“Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials ”, J of Skin, vol. 6, no. 6, p. s64, Nov. 2022, doi: 10.25251/skin.6.supp.64.